Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Martinsried / München, Germany, May 9, 2008 - (ABN Newswire) - Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
* Total revenues approx. 5.0 million EUR (Q1-2007: 6.9 million EUR) * Loss on EBIT basis of -7.9 million EUR (Q1-2007: -7.5 million EUR) * Cash and cash equivalents at closing date March 31, 2008 37.6 million EUR (December 31, 2007: 46.5 million EUR) * Key advances in product portfolio: positive phase II data for EndoTAG(TM)-1, European regulatory authority recommends granting of marketing authorization for Oracea®
Martinsried/Munich, May 9, 2008. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) achieved total revenues of 5.0 million EUR (Q1-2007: 6.9 million EUR). These revenues have been generated mainly from the commercialization of Eligard® in Europe. Sales revenues of Eligard® of approx. 1.5 million EUR were not realized in the first quarter of 2008, since the existing inventories were not delivered until the beginning of the second quarter of 2008. Taking this effect into consideration, and adjusting the revenues in last year's reporting period by a milestone payment at the same time, we find that MediGene's Eligard® revenues have increased compared to last year's reporting period. This also corresponds to the positive development of Eligard® prescriptions in the first quarter of 2008. Moreover revenues in the reporting period also include revenues from sales of Veregen(TM) in the USA to a small extent. The loss before interest and tax (EBIT) slightly increased to -7.9 million EUR compared to last year's reporting period (Q1-2007: -7.5 million EUR). This is due to a slight increase in R&D expenses and in selling, general, and administrative expenses.
Consolidated income statement (abbreviated) Q1-2008 Q1-2007 Change in T€ Total revenues 4,990 6,878 -27 % Cost of sales -3,397 -5,590 -39 % Gross profit 1,593 1,288 24 % Selling, general, and administrative expenses -2,608 -2,301 13 % Research and development expenses -6,866 -6,462 6 % Operating result -7,881 -7,475 5 % Result before income tax -9,461 -7,184 32 % Net loss for the period -8,796 -6,634 33 %
MediGene AG Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All Share, HDAX, MIDCAP, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;